Treatment.com AI Inc. to Rebrand as Rocket Doctor AI Inc., Aligning Business with Evolving Product Portfolio and Market Strategy
-
New name to take effect and begin trading on the Canadian Securities Exchange under the new ticker AIDR effective August 21, 2025
- Rebrand unites the company’s proprietary Global Library of Medicine (GLM) with Rocket Doctor Inc’s leading digital health platform to deliver scalable, AI-enhanced clinical and diagnostic tools
- Leveraging large language models, connected medical devices, and proprietary software to improve healthcare access for rural, remote, and underserved communities across North America
- Builds on successful April 2025 acquisition of Rocket Doctor Inc., marking a pivotal step towards commercialization and delivering measurable value to patients, providers, and shareholders
VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it is rebranding and reincorporating as Rocket Doctor AI Inc. This milestone reflects the Company’s continued evolution and its commitment to advancing its strategic vision.
Concurrently with the completion of the proposed name change, the Company’s trading symbol on the Canadian Securities Exchange will be changed from “TRUE” to “AIDR”. The new CUSIP number is 772924106 and the ISIN number is CA7729241066 for the Company’s common shares. The Company’s common shares will begin trading under the new ticker symbol on 21st August 2025.
The new name reflects the integration of the proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Rocket Doctor is a leading digital health platform and marketplace that empowers physicians to practice independently and deliver comprehensive care while connecting them to patients across North America. This includes rural and remote communities in Canada and patients on Medicaid and Medicare in the United States, leveraging large language models, bluetooth medical devices, and proprietary software.
The new stock symbol, AIDR, is intended to better represent the Company’s core focus on AI-driven administrative, diagnostic, clinical decision support and referral solutions that empower both healthcare professionals and patients.
This change follows the successful acquisition of Rocket Doctor Inc. in April 2025, which brought a strong complement to Treatment’s technology stack. Together, these accumulated assets position the Company to deliver scalable, AI-enhanced healthcare solutions at a time of growing demand for efficiency, accuracy, and improved care delivery.
Dr. Essam Hamza, CEO of Treatment.com AI Inc., comments: “We are very excited about this next chapter for the company. This name change marks a natural step in uniting our technology and service offerings under a single, stronger identity. Following the acquisition of Rocket Doctor, we are at an important inflection point. As we move toward the next phase of commercialization and prepare for our Q2 announcement, we remain focused on delivering practical; AI driven; clinically validated; scalable solutions and keeping our shareholders informed of our progress.”
Dr. William Cherniak, CEO of Rocket Doctor Inc., comments: “It’s been a fast-paced journey since joining the team at Treatment.com AI. We couldn’t be more thrilled to take the ethos and brand brought from our work across North America to now jointly power Rocket Doctor AI. There’s much more to go in our work of improving physicians’ practice of medicine, while in parallel increasing access to care for patients in need; this refined name makes clear our focus on technology as a critical component to achieving these objectives. Onward and upward!”
This strategic rebrand underscores the Company’s commitment to advancing accessible, AI-enhanced healthcare solutions and positions Rocket Doctor AI Inc. to deliver sustained value to patients, providers, and shareholders in the years ahead.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment.com AI’s products and services: www.treatment.com or email: info@treatment.com
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality comprehensive care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
To learn more about Rocket Doctor’s platform and services, visit www.rocketdoctor.ca (Canada) www.rocketdoctor.io (U.S.), or contact media@rocketdoctor.io .
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Dr. Bill Cherniak, CEO, Rocket Doctor
Email: bill@rocketdoctor.io
Media inquiries: media@rocketdoctor.io
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
